Lipocine (LPCN) Announces Positive Topline Data from LPCN 1111 Phase 2b as TRT

September 26, 2016 8:04 AM EDT
Get Alerts LPCN Hot Sheet
Trade LPCN Now!
Join SI Premium – FREE

Get daily under-the-radar research with's Stealth Growth Insider Get your 2-Wk Free Trial here.

Lipocine Inc. (Nasdaq: LPCN) reported positive top-line results from a Phase 2b clinical study of LPCN 1111, a novel oral testosterone replacement therapy ("TRT") product candidate. The primary objectives of the study were to determine the Phase 3 dose of LPCN 1111 along with the safety and tolerability of LPCN 1111 and its metabolites following oral administration of single and multiple doses in hypogonadal males.

The Phase 2b clinical trial was a randomized, open label, two-period, multi-dose PK study that enrolled hypogonadal males into five treatment groups. Each of the 12 subjects in a group received treatment for 14 days. Results of the Phase 2b study suggest that the primary objectives were met, including identifying the dose expected to be tested in a Phase 3 study. Good dose-response relationship was observed over the tested dose range in the Phase 2b study. The target Phase 3 dose met primary and secondary end points. LPCN 1111 was well tolerated with no drug-related severe or serious adverse events reported.

“We are pleased to report these positive top-line results, as these results reinforce our belief that LPCN 1111 represents a promising product candidate for once daily administration of testosterone," said Dr. Mahesh Patel, President and CEO of Lipocine Inc. "Based on this progress, we plan to meet with the United States Food and Drug Administration to discuss Phase 3 development plans."

About LPCN 1111

LPCN 1111, a novel prodrug of testosterone, originated with and is being developed by Lipocine as a next-generation oral testosterone product with potential for once daily dosing. LPCN 1111 comprises a novel prodrug different from the testosterone ester in LPCN 1021 and it uses Lipocine’s proprietary solubilization technology to improve systemic absorption to give effective testosterone levels.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, FDA, Management Comments

Add Your Comment